MENU
Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy…
We use cookies to make your website experience better. By accepting this notice and continuing to browse our website you confirm you accept our Terms of Use & Privacy Policy.
read more >>